[1]李霞,孔为民*,陈娇,等.中晚期宫颈癌同步放化疗生存情况及其预后相关因素分析[J].中国计划生育和妇产科,2018,(2):60-63.
　LI Xia,KONG Wei-min*,CHEN Jiao,et al.Survival status and prognostic factors of concurrent chemoradiotherapy in advanced cervical cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):60-63.
点击复制

中晚期宫颈癌同步放化疗生存情况及其预后相关因素分析
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年2期
页码:
60-63
栏目:
论著与临床
出版日期:
2018-02-25

文章信息/Info

Title:
Survival status and prognostic factors of concurrent chemoradiotherapy in advanced cervical cancer
作者:
李霞; 孔为民*; 陈娇; 宋丹; 焦思萌; 刘瑶; 商若天
首都医科大学附属北京妇产医院妇瘤科
Author(s):
LI Xia; KONG Wei-min*; CHEN Jiao; SONG Dan; JIAO Si-meng; LIU Yao; SHANG Ruo-tian
Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University,Beijing 100006,P.R.China
关键词:
宫颈癌; 同步放化疗; 生存率; 预后
Keywords:
cervical cancer; concurrent chemoradiotherapy; survival rate;  prognosis
分类号:
R 711.74
摘要:
目的观察同步放化疗治疗中晚期宫颈癌的远期疗效，并分析其预后的影响因素。方法回顾性分析2008年1月至2012年1月首都医科大学附属北京妇产医院收治的210例中晚期宫颈癌患者的临床资料，对其生存情况及预后相关因素进行分析。结果本研究中患者5年生存率为629 ％。单因素分析结果提示肿瘤病理类型、分化程度、放疗时间及临床分期是影响中晚期宫颈癌预后的独立因素(P<005)，而年龄、肿瘤最大径线及治疗前血红蛋白水平不是影响中晚期宫颈癌预后的独立因素（P>005）。将单因素分析中对预后有统计学意义的因素纳入比例
Abstract:
ObjectiveTo observe the long-term efficacy of concurrent chemoradiotherapy for advanced cervical cancer and to analyze its prognostic factors in advanced cervical cancer.MethodsThe clinical data of 210 cases with advanced cervical cancer between Jan 2008

参考文献/References:

［1］NOORDHUIS M G, EIJSINK J J, ROOSSINK F, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review ［J］. International Journal of Radiation Oncology Biology Physics, 2011, 79(2): 325-334. ［2］张丹，李恩孝．不同化疗方案同步联合放疗治疗中晚期宫颈癌的临床观察 ［J］．世界最新医学信息文摘（连续型电子期刊），2015，15（49）：54-55，72． ［3］SONODA K, YAHATA H, ICHINOE A, et al. Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-Fluorouracil versus weekly cisplatin in cervical cancer ［J］. Anticancer Research, 2015, 35(6): 3447-3454. ［4］王璐璐，孔为民．放疗新技术在子宫颈癌治疗中应用的进展 ［J］．中华妇产科杂志，2013，48（10）：792-794． ［5］MINIG L, PATRONO M G, ROMERO N, et al. Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB ［J］. World Journal of Clinical Oncology, 2014, 5(2): 86-92. ［6］范志刚．中晚期宫颈癌同步放化疗临床研究进展 ［J］．实用癌症杂志，2012，27（3）：309-311． ［7］GAFFNEY D K, ERICKSON-WITTMANN B A, JHINGRAN A, et al. ACR appropriateness criteria on advanced cervical cancer expert panel on radiation Oncology-Gynecology ［J］. International Journal of Radiation Oncology Biology Physics, 2011, 81(3): 609-614. ［8］KUZUYA Kazuo. Chemoradiotherapy for uterine cancer: current status and perspectives ［J］. International Journal of Clinical Oncology, 2004, 9(6): 458-470. ［9］李小凡，李永恒，高雨农，等．两种同步放化疗方案治疗Ⅰb 2-Ⅳa期子宫颈鳞癌的临床分析 ［J］．中华妇产科杂志，2013，48（10）：763-767． ［10］蔡胜男，韩克，张月香，等．同步放化疗中晚期宫颈癌患者预后的影响因素 ［J］．解放军医学院学报，2016，37（11）：1136-1141． ［11］TEH J, YAP S P, THAM I, et al. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors ［J］. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2010, 20(3): 428-433. ［12］VESCO K K, WHITLOCK E P, EDER M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force ［J］. Annals of Internal Medicine, 2011, 155(10): 698-705, W216. ［13］BRAL S, GEVAERT T, LINTHOUT N, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial ［J］. International Journal of Radiation Oncology Biology Physics, 2011, 80(5): 1343-1349. ［14］CREASMAN W T, KOHLER M F. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? ［J］. Gynecologic Oncology, 2004, 92(2): 525-529.

相似文献/References:

[1]冯学宇,乔银川,王好宁,等.823例宫颈癌机会性筛查结果分析[J].中国计划生育和妇产科,2010,(01):0.
　FENG Xue-yu,QIAO Yin-chuan,WANG Hao-ning ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(2):0.
[2]刘佳汭.保留盆腔自主神经的宫颈癌根治性手术[J].中国计划生育和妇产科,2010,(02):0.
[3]甘玉杰,熊小英,蔡春芳,等.血清SCCA、CA125、CA19-9与高危型人乳头状瘤病毒在宫颈癌及癌前病变中的表达及意义[J].中国计划生育和妇产科,2010,(04):0.
　GAN Yu-jie,XIONG Xiao-ying,CAI Chun-fang,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(2):0.
[4]肖春燕,陈桂珍,铁木帅龙,等.325例宫颈病变阴道镜检查结果分析[J].中国计划生育和妇产科,2010,(05):0.
　XIAO Chun-yan,CHEN Gui-zhen,TIEMU-Shuailong.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(2):0.
[5]钟茜,赵霞.宫颈癌诊治中的过度治疗与治疗不足[J].中国计划生育和妇产科,2013,(02):0.
　ZHONG Xi,ZHAO Xia,[J].Chinese Journal of Family Planning & Gynecotokology,2013,(2):0.
[6]安红梅,张雯,邓继红,等.昆明地区高危HPV病毒载量与宫颈病变和宫颈癌相关性[J].中国计划生育和妇产科,2013,(03):0.
　AN Hong - mei,ZHANG Wen,DENG Ji - hong *,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(2):0.
[7]闵爱萍,谢桂清,冷开容,等.Hepsin、Maspin在宫颈疾病中的表达及其临床意义[J].中国计划生育和妇产科,2013,(06):0.
　Min Ai-ping,Xie Gui-qing,Leng Kai-rong,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(2):0.
[8]朱书力,李力.树突状细胞对宫颈癌作用的研究进展[J].中国计划生育和妇产科,2014,(03):0.
[9]闵爱萍.刺猬蛋白在宫颈癌组织中的表达及其临床意义[J].中国计划生育和妇产科,2014,(07):0.
　MIN Ai-ping,[J].Chinese Journal of Family Planning & Gynecotokology,2014,(2):0.
[10]孙肖霞,王志莲,郝敏,等.胰岛素样生长因子轴与宫颈癌的相关性研究[J].中国计划生育和妇产科,2015,(05):0.
[11]陈娇,孔为民.局部晚期宫颈癌同步放化疗中药物选择的研究进展[J].中国计划生育和妇产科,2016,(11):0.

更新日期/Last Update: 2018-02-25